• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.660 +0.400 (+5.51%)
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 540,850
Open 7.280
Bid (Size) 7.660 (600)
Ask (Size) 7.670 (5,300)
Prev. Close 7.260
Today's Range 7.280 - 7.740
52wk Range 6.740 - 14.51
Shares Outstanding 63,500,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
October 07, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
October 01, 2026
From Arvinas Inc.
Via GlobeNewswire

Performance

52-Week Range 47.2% below 52-week high
7.660
6.7452W Low 14.5152W High
1 Week
6.741W Low 7.541W High

Arvinas, Inc. - Common Stock (ARVN) traded between $6.74 and $14.51 over the past 52 weeks and last traded at $7.66, 47.2% below its 52-week high. Over the past week it ranged between $6.74 and $7.54.

Past 12 Months
+12.0%
-7.7%
-4.5%
-29.1%
-33.2%
-21.2%
1W +$0.82
1M -$0.64
3M -$0.36
6M -$3.15
YTD -$3.81
1Y -$2.06

ARVN was -21.2% over the past year, -29.1% over six months, -33.2% year to date, +12.0% in the last week.

12 Months vs Market
ARVN
-21.2%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months ARVN returned -21.2% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.68× 3-mo avg
Today 540,850 3-mo avg 800.3K
1W
774.5K
1M
726.1K
3M
800.3K
6M
809.9K
YTD
824.2K
1Y
1.1M

ARVN most recently traded 540,850 shares against a 3-month average daily volume of 800.3K.

More News

Read More
News headline image
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
September 28, 2026
From Arvinas Inc.
Via GlobeNewswire
Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss ↗
May 12, 2026
Via Chartmill
News headline image
Arvinas to Participate in Upcoming Investor Conferences
September 03, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas (ARVN) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Via The Motley Fool
Topics Earnings
News headline image
Arvinas Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Transcript: Arvinas Q2 2026 Earnings Conference Call ↗
August 04, 2026
Via Benzinga
Topics Earnings
News headline image
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗
June 05, 2026
Via MarketBeat
News headline image
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 04, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Jefferies Global Healthcare Conference
May 29, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
May 13, 2026
Via Benzinga
News headline image
Arvinas Q1 Earnings Call Highlights ↗
May 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 05, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 01, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 11, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
February 24, 2026
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?
Yes, Arvinas, Inc. - Common Stock is publicly traded.
What exchange does Arvinas, Inc. - Common Stock trade on?
Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arvinas, Inc. - Common Stock?
The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
What is the current price of Arvinas, Inc. - Common Stock?
The current price of Arvinas, Inc. - Common Stock is 7.660
When was Arvinas, Inc. - Common Stock last traded?
The last trade of Arvinas, Inc. - Common Stock was at 10/20/26 04:00 PM ET
What is the market capitalization of Arvinas, Inc. - Common Stock?
The market capitalization of Arvinas, Inc. - Common Stock is 486.41M
How many shares of Arvinas, Inc. - Common Stock are outstanding?
Arvinas, Inc. - Common Stock has 486M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap